Karolinska Institutet, KI

Actar raises SEK 10 million to identify promising drug candidates from academia

Pressmeddelande   •   Okt 11, 2005 10:34 CEST

Actar AB discovers new drug molecules in collaboration with researchers from Karolinska Institutet
and other top Nordic universities. Actar identifies, validates and carries out projects in partnership with
academic groups to develop new innovative pharmaceuticals. The company provides proficiency and
resources from target validation stage to establishment of chemical proof of principle in model
systems. For more information, please visit www.actar.se

The Board of Directors for Actar AB ("the Company") decided on September 20, 2005 to increase the
Company's share capital, bringing in SEK 10 million. The shares were subscribed Karolinska
Development II and additional investors.

The purpose of the issue is to invest in the build-up of Actar’s laboratories at Karolinska Institutet as
well as driving the projects forward.

Actar currently runs three projects within drug discovery, two within the oncology area and one
inflammation project. "There is an enormous lack of interesting projects within the big pharmaceutical
companies today. We see a great potential in Actar’s as ability to provide the industry with high calibre
projects” says Dr. Conny Bogentoft, President and CEO of Karolinska Development II. "Around the
world there is a growing demand for treatment in these two highly attractive areas. Increasing the
resources at our disposal will further enhance our competitiveness" says Dr. Claes Post, Chairman of

For further information, please contact

David Jern, CEO, Actar AB
Phone +46 (0) 707 10 35 55
E-mail : david.jern@actar.se

Claes Post, President, Actar AB
Phone +46 (0) 702 76 81 68
E-mail : cpost@ctpost.se